The effect of anti-mu suppression of gammaM and gammaG on the production of gammaE by unknown
THE  EFFECT  OF  ANTI-MU  SUPPRESSION  OF  ~M  AND  ~G 
ON  THE  PRODUCTION  OF  ~/E* 
BY J.  M.  DWYER,  J.  T.  ROSENBAUM, AND S.  LEWIS 
(From The Department of Internal Medicine,  Yale University School of Medicine, New Haven, 
Connecticut 06510) 
The early precursors of antibody-producing cells in the mouse CB" lympho- 
cytes) have attached to their surface membrane immunoglobulin receptors (1, 2) 
specific for a very limited number of antigenic determinants (3-5).  These recep- 
tors develop in fetal life before the animal is introduced to antigens and in this 
period are largely of the ~M immunoglobulin class  (6,  7).  Combination of an 
antigen with these specific recognition units results in division and differentia- 
tion of many of these cells into mature antibody-secreting cells (plasma cells) (6, 
8). In general, the class of antibody secreted by these latter cells will be the same 
as the class of antibody present on the surface of the B lymphocytes from which 
these cells were derived (9,  10). Hence, primary immune responses are largely 
~/M in character. In humans, especially during fetal and early neonatal life, a 
large number of ~M-bearing lymphocytes also carry -/D on their surface, and it 
is not clear by what mechanism these cells differentiate to predominantly ~M- 
secreting cells (11). Such a phenomenon has not been described in the mouse. 
Not  all  ~/M-bearing  lymphocytes stimulated  by  antigen  become antibody- 
forming cells. Division of some of these cells results in an expanded pool of cells 
with the same recognition capacity, but with a recognition unit of the ~G class of 
immunoglobulin (11). These cells are the precursors of antibody-producing cells 
secreting ~G and B lymphocytes with ~A class immunoglobulin receptors (11). 
This ontogenetic sequence can occur to some extent in utero where the sequen- 
tial events are not driven by encounter with antigen (11,  12). 
How the production of  the other two major immunoglobulin classes ~E and ~D 
fit into the above scheme has not been determined. However, observation that 
the ~M to ~G to ~A sequence could be blocked by anti-mu chain antisera (13, 14) 
prompted this study of the effect of such antisera on ~E production. We have 
observed, as have others (15), that children with sex-linked agammaglobuline- 
mia can have absent ~M, ~G, and ~/A production and yet have detectable levels 
of serum ~E, ~E-bearing lymphocytes, and even atopic symptoms. Such observa- 
tions  suggest  that  ~E  development may be  independent of the  ontogenetic 
scheme for -/M, ~/G, and ~,A. In this paper we present evidence to support this 
concept. In the experiments described below, treatment of mice with anti-mu 
chain antisera failed to suppress the production of specific antibodies of the ~E 
class. 
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THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  • VOLUME  143, 1976  781 782  ANTI-MU  SUPPRESSION  AND  TE 
Materials and Methods 
Animals.  F,  litter  mates  from  C57BL/10  females  mated  with  DBA/1  males  were  used  as 
recipients of the anti-mu chain serum. As yE responsiveness in mice is variable but genetically 
controlled, we chose mice known to be good yE producers (16). The parent mice were obtained from 
the specific pathogen-free colony of the Biobehavioural Science Research Center of the University 
of Connecticut,  Storrs,  Conn.  Male  and female 6-wk-old Swiss  mice from the Yale  University 
Medical School colony were used to detect TG, antibodies using a  passive cutaneous anaphylaxis 
(PCA) '  technique. 200 g  male Sprague-Dawley rats (Charles River Breeding Laboratories,  Wil- 
mington, Mass.) were used in PCA tests to detect and titrate specific yE antibodies in mouse sera. 
Antisera.  Anti-mu chain sera, product B106,  lot No.  40832  and product B107,  lot No.  40900, 
were purchased from Meloy Laboratories Inc., Springfield, Va. These antisera were prepared in 
goats against a ~/M myeloma MOPC-104E. The antisera were rendered anti-mu specific by passage 
over immunoabsorbent columns containing MOPC-315B (yAh). The resulting preparations, tested 
by diffusion  in gel,  were  monospecific.  Special  attention was  paid to  the possible presence of 
antibodies to ~,-light chain determinants in these antisera. No light chain activity was found in 
testing these preparations against AKR-J,  BALB-cJ, C57BL/6J, and CBA-J mouse sera. It was 
necessary to remove by dialysis the sodium azide added to these antisera as a preservative before 
administering them to the mice. 
Injection  of Anti-Mu Chain Antisera and Immunization.  Mice were given their first injection 
of anti-mu chain sera or bovine gamma globulin (BGG) (control animals) within 24 h of birth. 0.05 
cm  3 of either agent was injected intraperitoneally (i.p.) daily for the first 4 days of life, while 0.1 
cm  3 was injected 9,  16,  23,  and 29 days after birth.  21  days after birth both experimental and 
control  animals were  given an  i.p.  injection of 0.1  ~g of twice-recrystallized ovalbumin  (OA) 
(Worthington Biochemical Corp.,  Freehold, N. J.) plus 1.12 mg of alum (AI(OH)3 gel) in a  total 
volume of 0.1 cm  a. Alum was prepared as previously described (17) and had a dry weight of 28 mg/ 
ml. 34 days after birth, all animals were lightly anesthetized and bled. Approximately 0.2 cm  3 of 
serum was obtained per animal. 
Antibody Measurements. 
PCA  REACTIONS.  Mouse sera contains two immunoglobulin classes, 7G, and 7E, that can bind 
to  the  surface  of mast cells  (18).  Antigen binding to  these surface  immunoglobulins releases 
histamine and other vasoactive substances from these cells, To measure anti-OA antibody of the 
yG, class, sera from control and anti-mu-suppressed mice were diluted (commencing with a  1:5 
dilution) and tested as follows. 0.03 cm  3 of diluted sera was injected intradermally into the shaved 
skin on the back of Swiss mice. Four injections of variously diluted antisera were given per back. 
All dilutions were tested simultaneously in three mice. 2 h later under ether anesthesia 0.15 cm  3 of 
saline with 0.7% OA and 0.4% Evans blue (Matheson, Coleman &  Bell, Rutherford,  N. J.) was 
injected intravenously via the retro-orbital plexus. After 30 min the animals were sacrificed, the 
skin removed from the back, and the diameter of blueing at the injection sites measured. The final 
titer of antibody activity was the highest dilution of serum causing blueing of 5 mm or more in 
diameter in at least two of three mice. 
Quantitation of anti-OA antibodies of the TE class were measured by a  PCA technique in rats. 
Mouse TE,  but not yG, will bind rapidly to rat mast cells (19).  Male Sprague-Dawley rats were 
anesthetized with an i.p. injection of 0.8 cm3/kg of sodium pentabarbital (Diabutal, Diamond Labs, 
Des Moines, Iowa). The backs of the rats were shaved, and 24 injections of 0.05 cm  3 of variously 
diluted sera were injected intradermally. 2 h later the rats were reanesthetized, and 1 cm  3 of saline 
containing 0.4% Evans blue and 0.7% OA was injected through the dorsal vein of the penis. After 
30 min, the animals were sacrificed and the skin of the back removed and read as described above 
for yG, measurements. 
QUANTITATION  OF  ~'M  AND  TG  ANTI-OA  ANTIBODIES.  A  passive  red  cell  hemagglutination 
technique was used.  Washed sheep red blood cells (SRBC) were washed and mixed for 4 min at 
room temperature with 3 mg of 0.1% CrC]3.6H20 (Mallinckrodt Inc., St. Louis, Mo.) and 3 ml of OA 
at  10 mg/ml.  The treated cells were washed five times and resuspended in normal saline at a 
Abbreviations used in thispaper: BGG, bovine gamma globulin; OA, ovalbumin; PCA, passive 
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concentration of 5% and then diluted 1:5 in phosphate-buffered saline. The ability of serial two-fold 
dilutions of test sera  (commencing at a  dilution of 1:10) to agglutinate these treated SRBC was 
used  to  quantitate total  antibody levels against  OA.  A  hyperimmune rabbit antisera  to  OA, 
supplied by Dr. P. Askenase, was used as a control. To measure ~/G antibody to OA, test sera were 
reacted with mercaptoethanol (Pierce Chemical Co., Rockford, Ill.). To 0.1 ml ofsera to be tested, 
0.3 ml of 0.133 M  mercaptoethanol was added and allowed to react for 2 h  at room temperature 
before the sera were tested. Several dilutions of sera were added to autotiter plates containing the 
treated  SRBC  and antibody titers measured  by detecting the dilution at which agglutination 
ceased.  15 dilutions were tested for each sample. 
DETECTION OF TGI, TO2, AND TA.  The presence of'rG~,  TG2, and ),A  was sought in  sera  by a gel 
diffusion technique using class-specific  antibodies. Precipitation lines  were sought with sera 
diluted 1:5 in saline. 
B-Lymphocyte Quantitation.  At the time the anti-mu or BGG-treated mice were sacrificed, 
some spleens were removed for  determination of  their B-cell  content. Spleens were gently teased 
between two glass slides  into a Petri dish containing modified Eagle's medium and 10% fetal  calf 
serum. The cells  so obtained were layered onto a Ficoll-Hypaque gradient and centrifuged for 45 
min at  4°C.  The single  cell  suspension removed from the  Ficoll-Hypaque interface  was wash.ed  and 
reacted with a polyvalent mouse anti-immunoglobulin serum raised in rabbits (Meloy Laborato- 
ries Inc.). After washing,  these cells were reacted for 30 rain at room temperature  with a 
fluoresceinated antirabbit immunoglobulin raised in goats (Hyland Div., Travenol Laboratories, 
Inc.,  Costa Mesa, Calif.).  After washing, these cells  were examined under ultraviolet  light,  and 
the  percentage of  fluorescent lymphocytes CB" cells)  was quantitated after  a differential  leukocyte 
count of  the preparation was performed. 
Statistical  Analysis.  Comparison of  the weights of  the mice in the control and anti-mu sera- 
treated groups, as well as the number of  B lymphocytes in the spleens of  mice from each group, 
were made by Student's t test  for unpaired data. For the antibody studies, the reciprocal of  the 
highest titers  measured were converted to the Log2, and from these values the mean Log2 values 
were obtained and compared by Student's  t  test  for  unpaired data. All calculations  were performed 
on a Monroe statistical  calculator,  Model 1930. 
Results 
Tables I and II contain all the data obtained from control and anti-mu-treated 
mice; Table III contains statistical  comparison of the data obtained from both 
groups. The protocol used did not cause significant runting in anti-mu-treated 
mice. Two mice, 3A and 4D (Table II), were clearly not immunosuppressed, and 
the  results  in  these  mice  were  excluded  from  the  statistical  analysis.  The 
administration of anti-mu chain sera, but not BGG, was generally immunosup- 
pressive causing a significant reduction in B lymphocytes in the spleen and anti- 
OA antibodies of the ~M, ~G, and ~/G, class. However, there was no significant 
reduction  in  anti-OA  antibodies  of the  ~E  class.  Nonspecific  ~G1  and  ~/G~ 
antibodies were frequently detected in both groups by a gel diffusion technique 
and probably represent maternally transmitted ~G. ~/A was not detected in the 
anti-mu-treated litter in which it was sought. 
Discussion 
The suppression of TM and ~/G production by anti-mu chain sera observed in 
the present studies is similar to that reported in other in vivo studies (13,  14), 
some  of which  have  used  germ-free  animals  (11).  Suppression  has  also  been 
observed in in vitro studies (20, 21). Such data strongly supports the concept that 
the virgin precursor "B" lymphocytes from which the humoral immune system 
develops express a surface receptor of~/M character.  When germ-free mice were 
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TABLE  I 
Antibody Production in Control Mice 
Litter  Mouse*  Weight 
Serum Immu-  Antibodies to OA 
noglobulins  ~ 
TE$  TG,$  TM  +  ~,G§  ~G~  ~G2 
TG 
Splenic 
lym- 
pho- 
cytes 
g 
1  C  18.2  320  5  1,280  80  +  + 
D  16.9  160  0  640  40  +  + 
% 
NT¶ 
NT 
B  13.6  640  20  120  1,280  +  + 
E  15.7  80  40  10,240  1,280  +  - 
F  14.9  80  40  5,120  320  +  - 
NT 
NT 
NT 
3  B  15.8  1,280  160  5,120  160  +  +  NT 
4  A  13.0  1,280  10  2,560  1,280  NT  NT 
B  15.0  640  40  5,120  5,120  NT  NT 
NT 
NT 
A  16.0  640  10"*  2,560  1,280  +  + 
B  15.7  80  10"*  640  160  +  + 
D  15.0  640  10"*  1,280  320  +  + 
NT 
NT 
NT 
B  9.3  320  40  640  160  +  + 
C  11.1  160  10  1,280  640  +  + 
D  12.8  160  40  640  160  +  + 
E  11.1  80  80  2,560  1,280  +  - 
57 
63 
49 
NT 
A  16.0  640  80  5,120  320  -  - 
B  16.0  0  0  0  0  +  - 
C  16.8  640  80  5,120  320  +  + 
43 
29 
62 
A  16.5  80  10  160  0  -  - 
B  15.7  640  160  10,240  160  +  + 
C  15.8  640  160  5,120  320  +  + 
D  16.9  640  80  2,560  320  +  + 
E  16.0  320  160  1,280  160  +  + 
47 
55 
38 
47 
39 
10 
A  17.4  640  40  10,240 
B  18.6  320  40  5,120 
C  16.7  1,280  40  2,560 
D  16.9  320  40  2,560 
A  15.5  320  80  5,120 
D  14.9  1.280  160  5,120 
E  14.5  1,280  40  640 
5,120  +  +  NT 
640  +  +  NT 
640  +  +  NT 
640  +  +  NT 
TA$$ 
640  +  +  +  58 
320  +  +  +  42 
160  +  +  +  59 
* Litter mates are compared in Table II. 
$ As measured by PCA reactions. 
§ As measured by passive hemagglutination after mercapteethanol treatment of serum. 
]1 As measured by gel diffusion. 
¶ Not tested. 
** Levels may have been higher than 10; insufficient serum available to test further. 
$$ ~/A present in serum measured by gel diffusion in litter 10. J.  M.  DWYER,  J.  T.  ROSENBAUM  9  AND  S.  LEWIS  785 
Litter 
TABLE  II 
Antibody Production  in Mice Treated with Anti-mu Serum 
Serum immuno- 
Antibodies to OA 
Mouse*  Weight  gl°bulins~ 
7E$  7G~  7M  +  7G  7G§  7G~  ~/G~ 
Splenic 
"B" lym- 
phocytes 
g 
B  9.3  40  0  0  0  + 
% 
NT¶ 
A  15.0  160  0  80  0  +  + 
C  19.0  40  0  0  0  +  + 
NT 
NT 
A**  15.0  320  0  320  80  +  + 
C  14.2  1,280  10  160  0  -  - 
D  16.3  320  10  0  0  -  - 
NT 
NT 
NT 
C  17.0  640  0  0  0  + 
D**  15.9  640  40  2,560  160  + 
NT 
NT 
5  D  9.2  160  0  0  0  -  -  NT 
A  11.6  0  0  0  0  +  + 
F  10.9  160  0  0  0  +  - 
D  14.5  80  0  0  0  -  + 
E  13.5  160  5  10  0  +  - 
F  16.0  160  0  0  0  +  + 
G  15.7  160  5  0  0  +  + 
27 
17 
8 
4 
8  F  13.3  320  5  40  10  +  + 
10 
E  16.0  0  10  0  0 
F  15.5  160  0  0  0 
G  16.2  80  0  0  0 
H  15.2  640  40  0  0 
B  14.8  160  0  0  0 
C  15.2  1,280  0  20  0 
F  11.8  320  10  40  0 
G  10.7  320  0  0  0 
32 
-  -  NT 
+  +  NT 
+  -  NT 
+  +  NT 
+  +  -  4 
+  -  -  15 
+  +  -  3 
+  -  -  7 
* Litter mates are compared in Table I. 
$ As measured by PCA reactions. 
§ As measured by passive hemagglutination after mercaptoethanol treatment of serum. 
[I As measured by gel diffusion. 
Not tested. 
** Mice  not  considered to  be  immunosuppressed and  not included  in  statistical  comparison of 
controls detailed  in Table III. 
$* 7A absent from sera of litter 10 as measured by gel diffusion. 
to  antigen,  but could produce 7M  (22). Such experiments, coupled with the 
observation that the order of appearance of  the major immunoglobulin  classes in 
both ontogeny and phylogeny follows the  sequence 7M,  7G,  7A,  led to  the 
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TABLE  III 
Comparison of the Antibody Response to OA of Control Mice and Mice Treated with 
Anti-Mu Chain Sera 
Treatment  Weight*  "B" cells$ 
_+  SD 
Geometric mean titer:  log2  _+  SEM 
~,G  +  -/M  "yG  ~G~  ,/E 
BGG 
g 
:251 812:271  49:194  :305 
15.27  _+  0.38  49.14  _+  10.22  10.86 ....  0.44  0.49  0.34  7.96  0.55 
:  :  :  : 262  2.61  0.14  0.70  0.61  1.19  7.01  Anti-mu  sera  14.24  +_  0.5  9.36  _+  2.16  1.83 ....  0.54  0.14  0.24  0.54 
BGG/Anti-mu 
ti§  1.65  10.9  12.55  13.41  9.16  1.16 
P  NS  <0.0001  <0.0001  <0.0001  <0.0001  NS 
§ ti, t  value for unpaired data. 
* Mean  -+  SEM. 
$ Mean  _+  SD. 
may arise from ~M-bearing cells (12). In a further sequential ontogenetic step, 
~A-bearing  cells  would arise  from  precursor  cells  bearing  ~G receptors  (12). 
While  all  studies  agree  on the  potent  immunosuppressive  ability of anti-mu 
chain sera, experiments using anti-~ chain sera in nongerm-free states have not 
demonstrated an equally potent suppressor effect (20, 21, 23). The reason for this 
is not certain,  but at least in vivo is probably related to the large amounts of 
maternal  ~/G present in the circulation  of newborn mice which may result  in 
rapid removal of administered anti-),G before it can act at a cellular level (24). It 
is this maternally derived ~/G that explains the inability of anti~M to eliminate 
serum ~G~ and ~G2. In the present study the profound effect of anti-mu sera on 
the endogenous production of ~/G1 to OA in the presence of detectable ~/G~ in 
serum  supports  this  idea.  In  vitro  studies  with  anti-~  or  anti-~2  sera  have 
resulted in suppression of both ~  and ~/2, but not ~M or ~A plaque-forming cell 
responses (20).  In such studies the anti-immunoglobulin  sera must simultane- 
ously compete with antigen stimulation,  and this may reduce the effectiveness 
of the anti-~ sera. The fact that anti-mu chain sera is completely suppressive in 
these experiments while anti~ chain sera is less potent could be explained if the 
affinity of~/G receptors for antigen is greater than that of~M receptors. It is well 
established  that  treatment  with  anti~A  affects only ~A production  (22,  24). 
Thus, for the three major immunoglobulin classes, a ~M to ~/G to ~/A sequence or 
a selective ~/M to ~G to ~/M development remain viable alternatives.  The latter 
alternative seems likely to be true at least for the gastro-intestinal  tract where 
evidence  for  ~M  precursors  differentiating  directly  into  ~A  cells  has  been 
reported (22). 
The placement of ~E and ~/D within an ontogenetic scheme for the develop- 
ment of humoral immunity has not been previously attempted. It is certain,  at 
least for man,  that  a  ~/M to ~G to ~/A to ~E  sequence is not likely,  as many 
patients with absent ~/A production have normal or even high levels of~E (25). J.  M.  DWYER~  J.  T.  ROSENBAUM,  AND  S.  LEWIS  787 
As we have observed patients without detectable yA-bearing lymphocytes who 
have normal levels ofyE, it is unlikely that the former observation is explained 
by a failure of y/A-bearing cells to become y/A-secreting plasma cells while still 
being able to differentiate to y/E-bearing precursor cells.  There is considerable 
clinical evidence to suggest that TE production and development may be inde- 
pendent of factors controlling the other major immunoglobulin classes.  The 
presence of detectable quantities of TE and even atopy has been observed by us 
and others (15) in children with an otherwise marked agammaglobulinemia. 
The production TE in vitro by primed lymphocytes exposed to anti-mu chain 
sera has been studied. Such lymphocytes were able to produce TE despite the 
presence of anti-mu chain sera (26). However, as this study utilized lymphocytes 
that had been exposed to antigen before antisera treatment, it indicates only 
that  cells producing TE  are  unaffected by anti-mu chain sera and does not 
answer questions about possible ontogenetic precursors of y/E-bearing cells. The 
data presented here strongly suggests that profound suppression of TM and yG 
production by anti-mu chain sera does not significantly reduce y/E production. 
At least three explanations for this observation can be forwarded. Firstly, stem 
cell precursors of B lymphocytes  thought to at least partially differentiate in the 
yolk sac and/or fetal liver (27) may develop either TE- or TA-bearing cells. Thus, 
anti-mu suppression would leave TE development intact. Secondly, yE-bearing 
cells may develop early in  fetal  life from y/M-bearing cells by a  genetically 
controlled differentiation pathway which is independent of antigen (12) and so 
escape the effects of anti-mu sera given at birth. Thirdly, TE-bearing cells may 
develop from yM-bearing cells  unable  to  differentiate along  the  TG  to  y/A 
pathway,  but  perhaps  with  T-cell  help  able  to  differentiate directly to  TE- 
bearing cells. 
The first explanation is the simplest, is consistent with the observation of TE 
production in congenital sex-linked agammaglobulinemia, and is strongly sug- 
gested,  but  not  established,  by  the  present data,  since  we  were  unable  to 
eliminate all B lymphocytes  from the spleen ofanti-mu-treated  mice. Increasing 
either the dose or frequency of injections caused severe runting and such poor 
survival as to be impractical. As both problems were encountered in the control 
mice as well, this may well be a function of too severe or frequent manipulations 
of such young mice. It is not currently possible to determine directly the number 
of residual B lymphocytes that have surface TE, but it seems unlikely that our 
mean residual 9% splenic B cells would all have TE recognition units. 
Anti-mu chain sera administered at birth could not affect y/E differentiation 
occurring earlier in fetal life. The human fetus can synthesize TM as early as 
10.5 wk of gestation and TG by 12 wk of gestation, while TA synthesis has not 
been demonstrated in  the  human conceptus.  Recently, TE  synthesis in  the 
human fetus was noted as early as 11 wk (28) in fetal lung and liver. While such 
studies have not been reported in the mouse, it is at least possible that very 
early development of y/E-producing precursor cells may allow the escape from 
anti-mu suppression reported here. 
Although the surface of the B lymphocyte  is the obvious site of action for anti- 
mu chain sera, its mode of action is uncertain. There is a natural recovery of 
immune competence,  occurring in  one  study  between  9  and  31  days  after 788  ANTI-MU  SUPPRESSION  AND  TE 
cessation of suppressive treatment  (22). It is possible that anti-mu-affected cells 
are alive but unable to differentiate along their TG to TA pathway. However, 
they may be capable of differentiation  along pathways less dependent on the 
integrity of the TM receptor.  So strong is the evidence for a  T-cell role in TE 
production and regulation that  it must at least be considered that T  cells are 
helping cells with totally or partially blocked mu receptors to differentiate along 
a normal pathway to TE production.  It has recently been shown that a  solubi- 
lized fraction of T cells can serve a  helper function in ~/E production,  and that 
this helper  activity can be removed by absorption of the  solubilized material 
with anti-mu chain sera (29). Our in vivo observations indicate that an anti-mu 
susceptible  helper  function  is  not  essential  for  normal  TE  production.  Con- 
versely, many observations report high TE levels in those situations where at 
least some T-cell functions are reduced.  In diseases such as Hodgkin's disease 
(30), Wiskott-Aldrich syndrome (31), and infectious mononucleosis (32) where T- 
cell function is suppressed and after T-suppressive manipulations  such as thy- 
mectomy (33), irradiation  (34), and treatment with antilymphocyte serum (35), 
TE production is enhanced.  Indeed,  a  soluble factor apparently  obtained from 
thymocytes has  been isolated  that  can  suppress TE  responses  (36).  Thus,  al- 
though the data at this stage is confusing, there can be little doubt that T cells 
are involved in the ontogeny of TE. 
The observation that T cells can both enhance and suppress TE production can 
only  be  explained  by  T-cell  subpopulations  with  different  functions,  and  it 
remains reasonable that one such subpopulation could be involved in the ontog- 
eny of TE-bearing cells. TE antibody function is able to bridge the gap between 
pharmacological  and  immunological  mechanisms  and  must  certainly  play  a 
constructive, if elusive, biological role. Better understanding of the relationship 
of TE to the rest of the immune system will improve our understanding  of this 
role. 
Summary 
Newborn mice were treated from the day of birth with either bovine gamma 
globulin or anti-mu  chain  sera.  The  latter was administered  using a  protocol 
known  to  produce  suppression  of TM,  TG,  and  TA  production.  Subsequent 
immunization with ovalbumin (OA) in alum was attempted to see if suppression 
ofTM, TG, and TA classes of antibody would also be accompanied by suppression 
of TE-producing  capacity.  TG and  TM  antibody to  OA  and  mercaptoethanol- 
resistant (TG) antibody to OA were measured by passive hemagglutination;  TG 
and TE anti-OA antibodies were measured by passive cutaneous anaphylaxis. 
Anti-mu  suppression  was achieved  with  significant  reduction  in TM  and  TG 
antibodies. TE antibodies were not affected, suggesting an ontogenetic develop- 
ment for TE-bearing lymphocytes independent of the previously described TM to 
TG to TA ontogenetic sequence. 
Received for publication 10 November 1975. 
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